Douglas Lu, DC
Family · San Antonio, TXNPI 1013925130
Payments from drug & device makers
Across 259 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$642
- Neurocrine Biosciences, Inc.$481
- Amgen$450
- Teva Pharmaceuticals USA, Inc.$406
- Johnson & Johnson$228
- EMD Serono, Inc.$180
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 26 | $642 |
| Neurocrine Biosciences, Inc. | 38 | $481 |
| Amgen | 31 | $450 |
| Teva Pharmaceuticals USA, Inc. | 21 | $406 |
| Johnson & Johnson(2 entities) | 12 | $228 |
| EMD Serono, Inc. | 10 | $180 |
| Livanova USA, Inc. | 9 | $176 |
| SK Life Science, Inc. | 10 | $173 |
| Eisai Inc. | 9 | $162 |
| GE HealthCare | 7 | $133 |
| Pfizer | 7 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Biogen | 4 | $84 |
| AstraZeneca | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 16 | $79 |
| Impel Pharmaceuticals Inc. | 5 | $79 |
| Kyowa Kirin, Inc. | 4 | $70 |
| AbbVie | 3 | $67 |
| Lilly USA, LLC | 4 | $64 |
| Avion Pharmaceuticals | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| MDD US Operations, LLC | 4 | $51 |
| Bioventus LLC | 2 | $46 |
| Corium, LLC | 3 | $44 |
| Octapharma USA, Inc. | 2 | $40 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Vertex | 1 | $30 |
| Sandoz | 2 | $28 |
| GRT US Holding, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sumitomo Pharma America, Inc. | 3 | $14 |
How this compares
$4,348 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 19 | $526 |
| Ibuprofen | 11 | $101 |
| Meloxicam | 15 | $14 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Ayoade AvworoSan Antonio$111K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.